$RLFTF Good news coming from China too!
Used google translate to pull the following out of the article.
The "king of stocks" under the epidemic should be Swiss biotech company Relief Therapeutics! Human trials of the company's drug RLF-100 for the treatment of new coronary pneumonia have recently obtained positive results, driving the company's market value to rise rapidly.
Since the beginning of the year, the stock price has risen by as much as 380 times, and the market value has surged by more than 10 times in the last 4 months.
Looking back at the end of July this year, the market value of Relief was less than 100 million Swiss francs (about 850 million Hong Kong dollars).
The company announced on August 10 that RLF-100 has obtained positive results in 21 human trials of patients with new coronary pneumonia under the authorization of the U.S. Food and Drug Administration (FDA) to expand its acquisition plan.
After the news was announced, the market value of Relief broke through 1.6 billion Swiss francs, and recently the market value has returned to around 1 billion Swiss francs.
RLF-100 is a synthetic agent. After being injected into the human body, it will concentrate in the lungs, stimulate the lung immune response and assist in the production of pulmonary surfactants, which is beneficial to the delivery of blood oxygen.
This patented drug came out in 2000 and was mainly used to treat acute respiratory distress and other lung diseases. After the outbreak broke out at the beginning of this year, Relief discovered that the drug helps protect cells from coronavirus attack, so he invested in the research and development of new coronary pneumonia treatments.
https://hk.on.cc/hk/bkn/cnt/finance/20201221/...M-x5okzHlc
Used google translate to pull the following out of the article.
The "king of stocks" under the epidemic should be Swiss biotech company Relief Therapeutics! Human trials of the company's drug RLF-100 for the treatment of new coronary pneumonia have recently obtained positive results, driving the company's market value to rise rapidly.
Since the beginning of the year, the stock price has risen by as much as 380 times, and the market value has surged by more than 10 times in the last 4 months.
Looking back at the end of July this year, the market value of Relief was less than 100 million Swiss francs (about 850 million Hong Kong dollars).
The company announced on August 10 that RLF-100 has obtained positive results in 21 human trials of patients with new coronary pneumonia under the authorization of the U.S. Food and Drug Administration (FDA) to expand its acquisition plan.
After the news was announced, the market value of Relief broke through 1.6 billion Swiss francs, and recently the market value has returned to around 1 billion Swiss francs.
RLF-100 is a synthetic agent. After being injected into the human body, it will concentrate in the lungs, stimulate the lung immune response and assist in the production of pulmonary surfactants, which is beneficial to the delivery of blood oxygen.
This patented drug came out in 2000 and was mainly used to treat acute respiratory distress and other lung diseases. After the outbreak broke out at the beginning of this year, Relief discovered that the drug helps protect cells from coronavirus attack, so he invested in the research and development of new coronary pneumonia treatments.
https://hk.on.cc/hk/bkn/cnt/finance/20201221/...M-x5okzHlc
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
